Brief Research Report: "Nothing About Us, Without Us": A Case Study of the Outer Sanctum Podcast and Trends in Australian Independent Media to Drive Intersectional Representation.

Alternative and independent sports media platforms create custom content that reflects a diversity of voices and representation of athletes, sports and issues that are not covered in meaningful ways in traditional sports media. While these new media outlets often set out to redress the lack of diversity and intersectional approaches to traditional sports media, they are also seeking ways to drive even more change. This in an interesting and important movement to interrogate as these platforms are not only predominantly unfunded, passion projects created by those marginalized groups. This brief research report provides a case study into this emerging alternative media space and its impact in driving change in an ever-evolving sports media landscape. We also discuss the problematic nature of intersectional-redressing work falling on those who still occupy the margins. This report uses a case study of an independent Australian rules football platform, The Outer Sanctum podcast, to focus on these key areas. The case study investigates how this outlet has worked to increase the visibility and profile of marginalized and underrepresented voices discussing football in new ways. It follows their journey as they have taken steps to improve their own diversity, enacting their mantra "nothing about us, without us," and proactively becoming more intersectional in their content producing journey. This research report will present key findings from the work of this media outlet to drive change and point to the learnings mainstream media can adopt to meaningfully embed intersectional approaches to sports media as core business.

OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.

BACKGROUND: We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period. We also compare the effect of aspirin and enoxaparin as DVT chemoprophylactic agents. METHODS: We conducted a single-centre randomised, double-blinded, placebo-controlled trial. 105 patients were randomised to receive either tranexamic acid or an equivalent volume of normal saline with enoxaparin used as DVT chemoprophylaxis. The primary outcome measure was thigh swelling. Blood loss and the incidence of blood transfusions was also recorded. Secondary outcome measures including postoperative functional scores and mobility, pain scores and length of stay. We also compared and pooled the results of a previous study with the same study intervention methodology which used aspirin as DVT chemoprophylaxis instead of enoxaparin. RESULTS: There were no statistically significant differences between the primary outcome of thigh swelling. There was significantly less intraoperative blood loss observed in the tranexamic acid (TXA) group (0.510 L, SD 0.210) compared with the control group (0.698, SD 0.301) ( p < 0.001). The estimated blood loss was also significantly less in the TXA group (1.130 L, SD 0.311) compared with the control group (1.48 L, SD 0.510) ( p < 0.001). Pooled data of both consecutive trials showed there was a statistically significant reduction in length of stay for those that received TXA (3.72 days, SD 0.83 versus 4.24 days, SD 0.97, p < 0.001). There was also a statistically significant increased risk of a transfusion in the control group as compared those that received TXA (OR 5.5, 1.188 to 25.449, p = 0.029). There was no difference in blood loss between DVT chemoprophylactic agents. INTERPRETATION: TXA is an effective agent in reducing blood loss in THR using the anterior approach and was not affected by choice of DVT chemoprophylaxis. Patients who received TXA had fewer transfusions and a reduction in their length of stay. The blood conserving effect of TXA was not associated with improved postoperative recovery across the measures of pain and mobility. CLINICAL TRIALS REGISTRATION: ANZCTR number: ACTRN12616000606482.

Use of Conjugated Dienones in Cyclialkylations: The Total Syntheses of (+/-)-Barbatusol, (+/-)-Pisiferin, (+/-)-Deoxofaveline, (+/-)-Xochitlolone, and (+/-)-Faveline.

Concise syntheses of five tricyclic diterpenoids are reported. The key reaction in each synthesis is a cyclialkylation of a functionalized arene with a Lewis acid-activated conjugated dienone to generate a 6,7,6-fused tricycle.